Brief: Vivos Therapeutics - Audit Reports For Fy2025 And Fy2024 Include Substantial Doubt About Going Concern
01/10/2026 11:10
BRIEF-Vivos Therapeutics - Audit Reports For Fy2025 And Fy2024 Include Substantial Doubt About Going Concern Oct 1 (Reuters) - Vivos Therapeutics Inc VVOS.O:
VIVOS THERAPEUTICS - AUDIT REPORTS FOR FY2025 AND FY2024 INCLUDE SUBSTANTIAL DOUBT ABOUT GOING CONCERN - SEC FILING
VIVOS THERAPEUTICS - DISMISSES BAKER TILLY US, LLP AS INDEPENDENT AUDITOR EFFECTIVE SEPT 29, 2026 - SEC FILING
Further company coverage: VVOS.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Vivos Therapeutics
See all newsBrief: Vivos Therapeutics Closes Acquisition Of Stake In Sod Sciences And 50% Interest In Pseudohypoxia Test, Opening A Potential Path To Access More Than 325,000 New Patients Through The Aha Channel
Brief: Vivos Therapeutics - Audit Reports For Fy2025 And Fy2024 Include Substantial Doubt About Going Concern
Brief: Vivos Therapeutics And South Palm Cardiovascular Associates Sign Definitive Agreements To Launch Regional Sleep Testing And Treatment Center
Vivos Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Vivos Therapeutics Q2 revenue rises 35% on service growth